P86.18 Prevalence, Clinical Characteristics and Survival of Patients with KRAS Mutant Lung Cancer in Argentina.

Between 20-35% of lung adenocarcinomas harbor a KRAS gene mutations (KRASm), most commonly in codon 12. With the development G12C covalent inhibitors as novel targeted therapies this population, there is renewed interest understanding clinical features and outcomes patients with mutant non-small cell cancer (NSCLC) worldwide. Clinical pathologic data were collected for two academic hospital, CEMIC Hospital Italiano de Buenos Aires (HIBA) Argentina. Molecular profiling tumor samples was done cohort using next generation sequencing (NGS) Oncomine Focus Assay (ThermoFisher) at both institutions (CEMIC/HIBA). Patients mutational status assessed by PCR/sanger also included. We estimated prevalence type testing methods. overall survival (OS) from date metastatic disease diagnosis Kaplan-Meier. The NGS 23% (35/150) 19% (16/84) sequencing. 10,6% (16/150) 6% (5/84) sanger accounted 41% entire of, followed G12V (24%), G12D (8%), G13C (6%) G12A (6%), G12S (4%), G13D G13S Q61H (2%) one commutation (2%). In 51 KRASm NSCLC included, median age (IQR) 66 years (61-72.5), higher proportion male (65%) smoking history (94%), histology (94%). total, 39 had which 90% received treatment. First line treatment included chemotherapy (n=33, 94%), immunotherapy (n=2, 6%). 20 (51%) second (n=15) (n=5). follow up 38 months (IC 95%: 21.6-47.9), 14.2 7.7-30.3). occur about 10.6% NGS. This similar to previously reported other western countries, than Latin America. Extensive molecular can identify potentially targetable help select subgroup that benefit trials targeting KRAS.